(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.04%) $83.41
(0.16%) $2.48
(0.12%) $2 341.70
(1.57%) $29.76
(0.34%) $992.10
(0.04%) $0.931
(0.15%) $10.66
(0.03%) $0.791
(-0.01%) $86.74
Live Chart Being Loaded With Signals
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system...
Stats | |
---|---|
Today's Volume | 188 151 |
Average Volume | 230 504 |
Market Cap | 27.91M |
EPS | $-0.280 ( Q1 | 2024-05-14 ) |
Next earnings date | ( $-0.540 ) 2024-08-05 |
Last Dividend | $0.0900 ( 2014-08-29 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.440 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00300 (0.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-12 | Shah Mahendra | Buy | 22 000 | Stock Option (Right to Buy) |
2024-06-12 | Onetto Nicole | Buy | 22 000 | Stock Option (Right to Buy) |
2024-06-12 | O'callaghan Brian | Buy | 22 000 | Stock Option (Right to Buy) |
2024-06-12 | Lee Frank D. | Buy | 22 000 | Stock Option (Right to Buy) |
2024-06-12 | Laporte Kathleen | Buy | 22 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
60.07 |
Last 93 transactions |
Buy: 3 954 307 | Sell: 1 352 975 |
Volume Correlation
Bolt Biotherapeutics, Correlation
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bolt Biotherapeutics, Correlation - Currency/Commodity
Bolt Biotherapeutics, Financials
Annual | 2023 |
Revenue: | $7.88M |
Gross Profit: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2023 |
Revenue: | $7.88M |
Gross Profit: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2022 |
Revenue: | $5.73M |
Gross Profit: | $838 000 (14.63 %) |
EPS: | $-2.30 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.97 |
Financial Reports:
No articles found.
Bolt Biotherapeutics, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2012-03-06 |
Last Dividend | $0.0900 | 2014-08-29 |
Next Dividend | $0 | N/A |
Payout Date | 2014-10-02 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $0.830 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.61 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
29 Aug 2014 | $0.0900 | 13 Aug 2014 | 30 Nov -0001 | 02 Oct 2014 |
10 Jun 2014 | $0.0900 | 24 Apr 2014 | 30 Nov -0001 | 09 Jul 2014 |
03 Mar 2014 | $0.0900 | 22 Jan 2014 | 30 Nov -0001 | 02 Apr 2014 |
30 Dec 2013 | $0.0900 | 27 Nov 2013 | 30 Nov -0001 | 15 Jan 2014 |
03 Sep 2013 | $0.0900 | 14 Aug 2013 | 30 Nov -0001 | 03 Oct 2013 |
03 Jun 2013 | $0.0700 | 24 Apr 2013 | 30 Nov -0001 | 05 Jul 2013 |
05 Mar 2013 | $0.0700 | 25 Jan 2013 | 30 Nov -0001 | 04 Apr 2013 |
30 Nov 2012 | $0.0700 | 21 Nov 2012 | 30 Nov -0001 | 18 Dec 2012 |
04 Sep 2012 | $0.0700 | 22 Aug 2012 | 30 Nov -0001 | 04 Oct 2012 |
04 Jun 2012 | $0.0500 | 26 Apr 2012 | 30 Nov -0001 | 06 Jul 2012 |
06 Mar 2012 | $0.0500 | 25 Jan 2012 | 30 Nov -0001 | 05 Apr 2012 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -5.57 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.441 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.517 | 1.500 | -6.86 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.68 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.52 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.255 | 1.500 | 9.70 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.137 | -1.500 | 7.72 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -52.18 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.652 | 2.00 | -0.551 | -1.101 | [0 - 30] |
freeCashFlowPerShareTTM | -1.657 | 2.00 | -0.829 | -1.657 | [0 - 20] |
debtEquityRatioTTM | 0.188 | -1.500 | 9.25 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.770 | 1.000 | 0.502 | 0.502 | [0.2 - 0.8] |
operatingProfitMarginTTM | -6.61 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -3.21 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0792 | 0.800 | -2.81 | -2.24 | [0.5 - 2] |
Total Score | -1.950 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.453 | 1.000 | -0.147 | 0 | [1 - 100] |
returnOnEquityTTM | -0.517 | 2.50 | -4.41 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.657 | 2.00 | -0.552 | -1.657 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.652 | 2.00 | -0.551 | -1.101 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00338 | 1.500 | -3.31 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -5.55 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.73 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Bolt Biotherapeutics,
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators